These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 20689467)

  • 1. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
    Berger M; Murphy E; Riley P; Bergman GE;
    South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
    Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
    J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
    Fasth A; Nyström J
    Acta Paediatr; 2007 Oct; 96(10):1474-8. PubMed ID: 17850391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
    Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
    J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.
    Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH;
    Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.
    Gardulf A; Borte M; Ochs HD; Nicolay U;
    Clin Immunol; 2008 Jan; 126(1):81-8. PubMed ID: 17964220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
    Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
    An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.
    Jolles S; Borte M; Nelson RP; Rojavin M; Bexon M; Lawo JP; Wasserman RL
    Clin Immunol; 2014 Feb; 150(2):161-9. PubMed ID: 24412910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.
    Ochs HD; Gupta S; Kiessling P; Nicolay U; Berger M;
    J Clin Immunol; 2006 May; 26(3):265-73. PubMed ID: 16783465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
    Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
    J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.